Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

News Daily News

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

May 09, 2025

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

Acute HF Patients Live Longer When Seen by Specialists

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

ACC/AHA Update Performance, Quality Measures for HF Care

News Daily News

ACC/AHA Update Performance, Quality Measures for HF Care

August 08, 2024

Randomized Trial Supports Using Hearts Donated After Circulatory Death

News Daily News

Randomized Trial Supports Using Hearts Donated After Circulatory Death

June 19, 2023

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

News Daily News

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Michael O'Riordan

November 22, 2022

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Getting More Women in CV Research Will ‘Take a Village’

News Daily News

Getting More Women in CV Research Will ‘Take a Village’

Yael L. Maxwell

August 09, 2021

Women Treated for Acute HF Report Worse QoL Than Men

News Daily News

Women Treated for Acute HF Report Worse QoL Than Men

March 12, 2021

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.